was successfully added to your cart.

Introducing IDDT – the InDependent Diabetes Trust.

Introducing IDDT

By introducingIDDT, Latest News

We are an organisation for people living with diabetes run by people living with diabetes. We recognise that when one person in a family lives with diabetes, this affects other family members and we offer support to partners and parents. We raise awareness of important issues for people with diabetes and provide information in non-medical language.

Read more…

A charity based in the UK listening to people with diabetes and their carers and supporting their needs. The Trust is run entirely by voluntary donations and we do not accept funding from the pharmaceutical industry in order to remain uninfluenced and independent.

The InDependent Diabetes Trust (IDDT) is a registered charity and was formed in 1994. We are concerned with listening to the needs of people who live with diabetes, understanding those needs and doing our utmost to offer help and support. We not only want to help those who actually have diabetes but also their carers – the husbands, wives, partners and parents, indeed, all of us who ‘live with diabetes’. We recognise that when one person in a family has diabetes, all other family members are affected to a greater or lesser extent and they all have views and needs which may be different from the person with diabetes, but nevertheless are important.

The Trust was set up to look at some of the day to day difficulties of living with diabetes, the worries, fears and concerns that perhaps we don’t talk about at the hospital clinic- the ones that many of us experience and understand because we actually live with diabetes. As a charity, IDDT has a Board of Trustees and all our Trustees either have diabetes or have family members with diabetes. So we all know first hand that while diabetes doesn’t rule our lives, it is an important part of them. It needs care and attention, it can be a nuisance and it is not without it’s problems!

GP practices in England are to be paid an average of £3,000 a year in bonuses to prescribe weight loss drugs to patients

By Latest News

The government is adding incentive payments of up to £3,000 to the GP contract starting in April but the payments will only apply to Mounjaro. This will be the first time weight loss drugs have been made part of the GP contract with £3,000 available for prescribing Mounjaro to the maximum number of eligible patients.

Click here for more details

MHRA issues strengthened warnings on acute pancreatitis,

By Latest News

…including necrotising and fatal cases for GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists

The product information for all Glucagon-Like Peptide-1 (GLP-1) receptor agonists and dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) receptor agonists has been further updated to highlight the potential risk of severe acute pancreatitis with these products, including rare reports of necrotising and fatal pancreatitis. (Published 29th January 2026)

Click here for more details

Abbott Laboratories have issued with a field safety notice warning of a fault affecting certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus glucose sensors

By Latest News

Abbott Laboratories, the manufacturer has discovered that some sensors could give inaccurate low glucose readings, which could lead to inappropriate treatment decisions and potentially serious harm among people with diabetes. The issue is limited to the FreeStyle Libre 3 and Libre 3 Plus sensors and Abbott stressed this issue does not apply to any other Libre sensors, apps or readers available in the UK.

Click here for more details

Hypurin Porcine insulin vials discontinuation

By Latest News

On 23 July 2025, the DHSC issued a Medicine Supply Notification for Wockhardt’s Hypurin Porcine insulin range in 10ml vials which are being discontinued.

This includes:

  • Hypurin Porcine Isophane 100units/ml suspension for injection 10ml vials (from August 2025)
  • Hypurin Porcine Neutral 100units/ml solution for injection 10ml vials (from January 2026)
  • Hypurin Porcine 30/70 Mix 100units/ml suspension for injection 10ml vials (from March 2026)

Click here for more details

Important Update on Hypurin® Porcine Insulin Vials and mypen®2 Insulin Delivery Pen

By Latest News

27 October 2025

Wockhardt has recently announced the discontinuation of Hypurin® Porcine Vials. As a result, all patients currently using vials will need to have their insulin prescriptions changed.

  • The discontinuation of Hypurin® vials does not affect the supply of Hypurin® Porcine Cartridges.
  • To support continued use of Hypurin, Wockhardt now offers a compatible, reusable insulin pen the mypen®2.
  • The mypen®2 Is now available on NHS prescription

Click here for more details about the discontinuation and the mypen®2

Are you having difficulty obtaining the new mypen2? Read more…

We are aware that some people are having difficulty obtaining the mypen 2 to use their Hypurin porcine insulin cartridges, often because they are told by their GP surgery or pharmacy that it is not available. This is NOT the case and the advice from a pharmacist who has managed to obtain the new pen for her patient is as follows.

EMIS is the computer system used by many GP practices in England and they have added the MyPen2 to their system but it will not start to appear until the next update which will take a while to come through. In the meantime, if people are faced with difficulty, the advice is that they should ask their GP to do a handwritten prescription for the myPen2 rather than a computer generated one. This should then be taken to a pharmacy. The pharmacy can then obtain the pen from AAH Pharmaceuticals or Alliance Healthcare.

Hypurin Porcine in Australia

By Latest News

The global manufacturer of HYPURIN Porcine has stopped producing vial presentations, but the product will still be available in cartridge form, which requires a pen for administration. ​ Aspen has been managing access to HYPURIN Porcine products through the Special Access Scheme (SAS) for years and is now transferring full management to HL Pharma Pty Ltd. HL Pharma will provide a streamlined service with a focus on personalised care. ​ This change will take effect on 1 October 2025. ​

Click here to read/download the letter from Aspen Australia

HbA1c errors led to some people being wrongly diagnosed with Type 2 diabetes

By Latest News

At least 55,000 people will need repeat blood tests after errors were discovered in machines used to diagnose Type 2 diabetes. NHS England has confirmed that up to 10% of NHS laboratories in England have been affected by the errors in the HbA1c machines used to diagnose Type 2 diabetes. The effects of this mean that some people have been wrongly diagnosed with Type 2 diabetes and some have been prescribed unnecessary medication.

Click here for more details

NICE sets out a shake-up in Type 2 diabetes care

By Latest News

Millions of people are set to benefit from earlier access to newer Type 2 diabetes treatments as part of NICE’s commitment to the 10-Year Health Plan for the NHS. The draft guidelines from NICE moves away from a ‘one-size-fits-all’ approach, shifting from automatically starting everyone on one medicine to personalised treatment plans that aim to prevent heart failure, heart attacks and other serious medical problems.

Click here for more details

People need ongoing support after obesity treatment

By Latest News

On August 5th 2025, the National Institute for Health and Care Excellence (NICE) released updated guidance recommending that healthcare providers offer structured, ongoing support to patients after they complete obesity treatment or stop taking weight-loss medications.

Research shows that many people regain weight after stopping treatment if they don’t get the right help, which can negatively affect both their physical and mental health.

Click here for more details

From Autumn 2025, the eligibility for a COVID-19 vaccination in the UK is changing

By Latest News

The JCVI have stated that there is now a high population immunity to COVID-19, additional COVID-19 doses provide very limited, if any, protection against infection and any subsequent onward transmission of infection.

In the UK, the government has therefore decided that, from Autumn 2025, only the following groups of people will be offered a COVID-19 vaccination:

  • adults aged 75 years and over
  • residents in a care home for older adults
  • people aged 6 months and over who are immunosuppressed (for more information see the NHS website: COVID-19 vaccine – NHS)

Click here for more details

MHRA Press Release on weight loss drugs!

By Latest News

On 5th June 2025, the Medicines and Healthcare products Regulatory Agency (MHRA) issued a press release to remind women with diabetes also taking the popular medicines for weight loss to use safe and effective contraception. In some cases, it is advised that women stop the medication at least two months before trying to get pregnant.

The GLP-1 medicines brand names include Ozempic, Mounjaro, Wegovy, Saxenda and Victoza and the key points are
Click here for more details

InDependent Diabetes Trust